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Abstract 
Background: Radiation therapy plays an increasingly important role in the treatment of patients 
with non-small-cell lung cancer (NSCLC). The purpose of the present study is to assess the survival 
outcomes of radiotherapy treatment compared to other treatment modalities and to determine the 
potential role of advanced technologies in radiotherapy on improving survival. 
Methods: We used cancer incidence and survival data from the Surveillance, Epidemiology, and End 
Results database linked to U.S. Census data to compare survival outcomes of 288,670 patients with 
stage I-IV NSCLC treated between 1999 and 2008. The primary endpoint was overall survival. 
Results: Among the 288,670 patients diagnosed with stage I-IV NSCLC, 92,374 (32%) patients 
received radiotherapy—almost double the number receiving surgery (51,961, 18%). Compared to 
other treatment groups and across all stages of NSCLC, patients treated with radiotherapy showed 
greater median and overall survival than patients without radiation treatment (p < 0.0001). 
Radiotherapy had effectively improved overall survival regardless of age, gender, and histological 
categorization. Radiotherapy treatment received during the recent time period 2004 – 2008 is 
correlated with enhanced survival compared to the earlier time period 1999 – 2003. 
Conclusion: Radiation therapy was correlated with increased overall survival for all patients with 
primary NSCLC across stages. Combined surgery and radiotherapy treatment also correlates with 
improved survival, signaling the value of bimodal or multimodal treatments. Population-based 
increases in overall survival were seen in the recent time period, suggesting the potential role of 
advanced radiotherapeutic technologies in enhancing survival outcomes for lung cancer patients. 
Key words: non-small cell lung cancer (NSCLC), radiotherapy, treatments, overall survival  
Introduction 
Lung cancer is a leading cause of cancer-related 
death in the United States, with non-small-cell lung 
cancer (NSCLC) accounting for approximately 85% of 
cases [1]. Over 60% of patients with NSCLC require 
radiotherapy at least once during their course of 
disease [2, 3], and radiotherapy plays an increasingly 
pivotal role in local tumor control and survival 
outcomes [4-8].  
Recent years have witnessed significant 
advances in radiotherapeutic technology [9], with the 
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increasing utilization of stereotactic techniques, 
intensity modulated radiation therapy, 4-dimensional 
treatment planning, and image guidance for the 
treatment of stage-specific NSCLC [3, 10-14]. Aided 
by novel radiotherapeutic technologies, radiotherapy 
has made remarkable progress in achieving high local 
tumor control particularly in the treatment of 
inoperable NSCLC [15, 16]. More recently, targeted 
therapy and immunotherapy in combination with 
radiotherapy has shown promise in improving 
treatment outcomes and survival [3, 17-22]. 
In light of these developments, we hypothesized 
that radiotherapy treatment, facilitated by 
technological advances in radiation imaging, 
planning, and delivery, is correlated with enhanced 
survival outcomes. We sought to test this hypothesis 
through a comprehensive retrospective study of the 
Surveillance, Epidemiology, and End Results (SEER) 
data to provide insight into patterns of care and the 
relationship between survival and radiotherapy 
treatment between the years 1999 and 2008. 
Methods and Materials 
Data Source and Study Population 
The study analyzed the SEER 17 Registry 
(1999–2008) from the National Cancer Institute, the 
comprehensive source of cancer incidence and survi-
val data in the United States. Within SEER, we 
identified 288,670 patients with pathologically 
confirmed NSCLC between 1999 and 2008. The 
specific histologic types selected were adenocarcin-
oma, squamous cell carcinoma, large-cell carcinoma, 
carcinoid, and others. The use of radiotherapy, 
typically within 6 months of initial diagnosis, was 
abstracted from local tumor registries and reported to 
SEER. The following information was obtained and 
analyzed: age at diagnosis, gender, race, marital 
status, histology subtypes, the 5th and 6th editions of 
American Joint Cancer Committee (AJCC)/TNM 
staging category [23], SEER stage, and treatment type 
(radiotherapy, surgery, combined radiotherapy and 
surgery, or neither radiotherapy nor surgery). There 
was no difference in AJCC staging groups between 5th 
and 6th editions. Information about the use of 
adjuvant chemotherapy was not available within the 
SEER data and therefore was not included in our 
analysis. 
Statistical Analysis 
The primary endpoint of this study was overall 
survival (OS). The Pearson χ2 test was used to 
determine unadjusted associations between radio-
therapy treatment and categorical variables of 
interest, including age, gender, stage distribution, and 
histology. OS was defined as the time between diagn-
osis and death. The Kaplan-Meier survival estimates 
method was used for generating the survival curves, 
and the log-rank test was used to assess the 
differences between the survival curves. Cases were 
also divided into two 5 year-of-diagnosis periods 
(1999–2003 and 2004–2008) for analysis of temporal 
trends. Results were considered statistically signifi-
cant when P value <0.05. All P values were two-sided. 
Results 
Patient Characteristics 
Using the SEER database, we identified a total of 
288,670 patients diagnosed with stage I–IV NSCLC 
between 1999 and 2008. Baseline patient, tumor, and 
treatment-related characteristics were provided in 
Table 1. The male to female ratio was 1.19:1. 
Regarding race, 238,147 (82.5%) patients were white, 
and 31,100 (10.8%) black. 99,495 (34.5%) patients were 
aged <65 years, while 189,175 (65.5%) patients were 
aged ≥65 years. 147,399 (51.1%) patients were married, 
and 129,918 (45%) unmarried. In terms of AJCC stage, 
53,764 (18.6%) patients were stage I, 10,937 (3.8%) 
stage II, 74,570 (25.8%) stage III, and 117,228 (40.6%) 
stage IV. Using the SEER staging system, 51,802 (18%) 
patients had localized tumor, while 69,650 (24.1%) 
had regional tumor. In terms of histology, 98,141 
(34%) had adenocarcinoma, 60,057 (20.8%) had 
squamous cell carcinoma, 11,669 (4.1%) had large-cell 
carcinoma, 115,219 (39.9%) had others, and 3,584 
(1.2%) had carcinoid (Table 1). 
Overall Survival and Its Associations with 
Patient Characteristics 
The median OS for all patients (n=288,670) was 8 
months. The 1-year, 2-year, 3-year, 5-year OS were 
40%, 26.3%, 20.2%, and 14.5%, respectively (Table 1; 
Figure 1). 
Gender, race, age, marital status, AJCC stage, 
SEER stage, and histology were all significantly 
associated with survival outcomes (Table 1). Young 
white married female patients with lower stage 
NSCLC had a higher median and OS. 17.2% of 
females had a 5-year OS, compared to 12.2% of males 
(P<0.0001). Patients aged <65 years had a 5-year OS of 
19.6% (median survival, 11 months), while patients 
aged ≥65 years have a 5-year OS of 11.7% (median 
survival, 7 months) (P<0.0001). Stage I NSCLC had 
highest proportion of 5-year OS at 45.2%, with a 
median survival of 49 months (P<0.0001). Stage IV 
had the lowest proportion of 5-year OS at 2.4%, with a 
median survival of 4 months (P<0.0001). Five-year OS 
was more favorable for localized (43.5%, median 
survival, 45 months) than regional (19.9%, median 
survival, 15 months) tumors (P<0.0001). 
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Figure 1. A. Among all primary NSCLC patients (n=288,670), 18% of patients received surgery, 4% combined surgery and radiotherapy, 32% radiotherapy, and 45% 
neither surgery nor radiotherapy. Overall, the proportion of NSCLC patients receiving radiation (32%) is almost double that receiving surgery (18%). B-E. Survival 
plots for NSCLC patients (n=288,670) between treatment types show that, across all stages, NSCLC treated with radiotherapy is associated with greater OS than 
NSCLC treated without surgery or radiation. While surgical treatment is correlated with the greatest OS across all stages of NSCLC, the survival distribution of 
combined surgery and radiation treatment begins to match that of surgery for patients with stage II/III NSCLC. 
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Table 1. Patient characteristics and survival. 
Characteristics   # Cases  % Pts MS ( 95% CI ) % of Overall Survival (95% CI)  P Value 
    months 1 Year  2 Year   3 Year  5 Year   
Gender               <0.0001 
Male  156,721  54.3  7 (na, na)  36.9 (36.6, 37.1)  23.1 (22.9, 23.3)  17.3 (17.1, 17.5)  12.2 (12.0, 12.4)   
Female  131,949  45.7  10 (9,10)  43.8 (43.6, 44.1)  30.2 (30.0, 30.5)  23.8 (23.5, 24.0)  17.2 (17.0, 17.5)   
Race               <0.0001 
White  238,147  82.5  8 (na, na)  40.1 (39.9, 40.3)  26.6 (26.4, 26.8)  20.5 (20.3, 20.6)  14.8 (14.6, 14.9)   
Black  31,100  10.8  7 (7, 8)  36.8 (36.2, 37.3)  22.3 (21.8, 22.8)  16.8 (16.3, 17.2)  11.7 (11.2, 12.1)   
Other/Unk  19,423  6.7  10 (na,na)  44.7 (44.0, 45.5)  29.8 (29.1, 30.5)  22.8 (22.1, 23.4)  15.5 (14.9, 16.1)   
Age                <0.0001 
<65  99,495  34.5  11 (na, na)  47.0 (46.7, 47.3)  32.0 (31.7, 32.3)  25.7 (25.4, 26.0)  19.6 (19.4, 19.9)   
≥65  189,175  65.5  7 (na, na)  36.4 (36.2, 36.6)  23.3 (23.1, 23.5)  17.4 (17.2, 17.6)  11.7 (11.5, 11.9)   
Marital Status               <0.0001 
Married  147,399  51.1  10 (na, na)  43.8 (43.6, 44.1)  29.5 (29.2, 29.7)  23.1 (22.8, 23.3)  16.9 (16.7, 17.1)   
Not Married  129,918  45.0  7 (na, na)  35.8(35.6, 36.1)  22.8 (22.6, 23.1)  17.1 (16.8, 17.3)  11.8 (11.6, 12.0)   
Unknown  11,353  3.9  8 (7, 8)  39.1 (38.1, 40.0)  25.8 (24.9, 26.7)  19.6 (18.8, 20.4)  13.9 (13.2, 14.7)   
AJCC Stage               <0.0001 
Stage I  53,764  18.6  49 (48, 50)  78.7 (78.3, 79.0)  65.7 (65.3, 66.2)  56.9 (56.4, 57.3)  45.2 (44.7, 45.8)   
Stage II  10,937  3.8  27 (26, 29)  71.0 (70.1, 71.9)  53.3 (52.3, 54.3)  42.3 (41.2, 43.3)  29.8 (28.7, 30.9)   
Stage III  74,570  25.8  9 (9, 10)  41.7 (41.3, 42.1)  24.0 (23.7, 24.3)  16.6 (16.3, 16.9)  10.6 (10.4, 10.9)   
Stage IV  117,228  40.6  4 (na, na)  19.7 (19.5, 20.0)  8.5 (8.3, 8.7)  4.9 (4.7, 5.0)  2.4 (2.3, 2.5)   
SEER Stage               <0.0001 
Localized  51,802  18.0  45 (44, 46)  76.7 (76.5, 77.2)  63.5 (63.0, 63.9)  54.9 (54.4, 55.4)  43.5 (43.0, 44.0)   
Regional  69,650  24.1  15 (15, 16)  55.7 (55.3, 56.1)  37.5 (37.1, 37.9)  28.5 (28.1, 28.9)  19.9 (19.5, 20.2)   
Histology               <0.0001 
Adenocarcinoma  98,141  34.0  10 (na, na)  45.5 (45.1, 45.8)  31.0 (30.7, 31.3)  24.1 (23.8, 24.4)  17.0 (16.7, 17.3)   
Squamous Ca  60,057  20.8  10 (na, na)  44.9 (44.5, 45.3)  29.0 (28.6, 29.4)  21.9 (21.5, 22.2)  15.6 (15.3, 16.0)   
Large Cell Ca  11,669  4.1  8 (7,8)  36.5 (35.6, 37.4)  22.5 (21.7, 23.3)  17.4 (16.7, 18.2)  12.7 (12.0, 13.4)   
Carcinoid  3,584  1.2  N/A  93.8 (93.0, 94.6)  90.6 (89.6, 91.6)  87.8 (86.4, 88.8)  82.6 (81.1, 84.1)   
Others  115,219  39.9  6 (na, na)  31.7 (31.4, 31.9)  19.5 (19.2, 19.7)  14.4 (14.2, 14.6)  10.0 (9.8, 10.2)   
All Patients  288,670  100  8 (na, na)  40.0 (39.9, 40.2)  26.3 (26.2, 26.5) 20.2 (20.1, 20.4)  14.5 (14.3, 14.7)   
Note: MS=median survival, pt= patients, CI= confidence interval, ca= carcinoma, N/A= an interval that was too narrow to be computable. 
 
Treatment Modality and Survival 
Among all primary NSCLC patients, 18% of 
patients received surgery, 4% combined surgery and 
radiotherapy, 32% radiotherapy, and 45% neither 
surgery nor radiotherapy (Figure 1, Table 2A, Table 
2B and Table 2C). Overall, the proportion of NSCLC 
patients receiving radiation (32%) was almost double 
that receiving surgery (18%) (Figure 1, Table 2A, 
Table 2B and Table 2C). The majority of patients with 
stage I/II NSCLC received surgery, whereas patients 
with stage III/IV NSCLC were more likely to receive 
radiation therapy. Combined surgery and 
radiotherapy was used most frequently when treating 
stage II NSCLC (Figure 1, Table 2A, Table 2B and 
Table 2C). 
Survival plots for NSCLC patients between 
treatment types were shown in Figure 1. NSCLC 
treated with radiotherapy alone was associated with 
greater OS than NSCLC treated without surgery or 
radiation (Figure 1). While surgical treatment was 
correlated with the greatest OS across all stages of 
NSCLC, the survival distribution of combined 
surgery and radiation treatment begins to match that 
of surgery for patients with stage II/III NSCLC. 
The Influence of Radiation Therapy on Overall 
Survival 
In the patients who did not receive surgery, 
radiotherapy improved survival across all stages of 
NSCLC. The overall median survival gain was 4 
months, with the most pronounced gains found in 
stage II/III lung cancer patients (Table 3). The median 
survival gain for stage I, II, III, and IV was 6 months, 8 
months, 7 months, and 2 months, respectively. 
Moreover, in all patients with NSCLC, treatment with 
radiotherapy improved OS more than treatment 
without (Figure 2). 
Radiotherapy had effectively improved OS 
regardless of age, gender, and histological categoriza-
tion (Table 4). 
Comparison of Overall Survival Between Time 
Periods 
Between the time periods of 1999–2003 and 
2004–2008, OS improved by 2% (Table 4, Figure 3). 
This improvement in survival outcomes is significant 
for patients with stage I, stage III, and stage IV 
NSCLC (P<0.0001, Figure 3). Among patients 
receiving radiotherapy (n=93,633), treatment received 
during the between 2004–2008 was correlated with 
enhanced survival compared to 1999–2003 (Figure 
3E-H). Surgical treatment improved survival for stage 
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III and stage IV NSCLC (Figure 4). Notably, stage I 
NSCLC showed significant increase in survival with 
radiotherapy treatment but not with surgery 
(P<0.0001). For patients who did not receive surgery 
or radiotherapy (n=131,022), survival improved 
across every stage, suggesting that overall quality of 
care improved, or patient selection was favorable 
(Figure 5). 
 
Table 2A. Radiation and survival stratified by age 
Radiation   No Radiation  Radiation Difference 
MS 95% CI   MS 95% CI   *P value MS Gain 
In 151,453 patients who did not have surgery and age ≥ 65 years 
18 17, 19  10 10, 11  <0.0001 8 
13 13,15  7 6, 8  <0.0001 6 
10 na  3 3, 4  <0.0001 7 
4 na  2 na  <0.0001 2 
7 na  3 na  <0.0001 4 
 
In 73,202 patients who did not have surgery and age < 65 years 
20 19, 22  19 17, 20  <0.0001 1 
18 15, 21  9 8, 11  <0.0001 9 
13 13, 14  7 7, 8  <0.0001 6 
6 na  4 na  <0.0001 2 
8 na  6 5, 6  <0.0001 2 
Table 2B. Radiation and survival stratified by gender 
Stage Radiation   No Radiation  Radiation Difference 
MS 95% CI   MS 95% CI   *P value MS Gain 
In 124,301 patients  who did not have surgery and were male 
I 16 16, 17  10 10, 11  <0.0001 6 
II 14 13, 15  7 6, 8  <0.0001 7 
III 11 10, 11  4 na  <0.0001 7 
IV 5 na  3 2, 3  <0.0001 2 
Total 7 na  3 na  <0.0001 4 
 
In 100,354 patients who did not have surgery and were female 
I 21 20, 22  13 12, 14  <0.0001 8 
II 16 15, 18  8 7, 9  <0.0001 8 
III 12 12, 13  4 4, 5  <0.0001 8 
IV 5 na  3 na  <0.0001 2 
Total 8 na  4 na  <0.0001 4 
Table 2C. Radiation and survival stratified by histology 
Stage Radiation   No Radiation  Radiation Difference 
MS 95% CI   MS 95% CI   *P value MS Gain 
In 43,467 patients who did not have surgery squamous cell carcinoma 
(SCC) 
I 16 15, 17  9 9, 10  <0.0001 7 
II 13 12, 15  7 5, 9  <0.0001 6 
III 11 na  5 4, 5  <0.0001 6 
IV 5 na  3 na  <0.0001 2 
Total 9 na  4 4, 5  <0.0001 5 
 
In 181,188 patients who did not have surgery and had non-SCC 
I 12 19, 20  12 12, 13  <0.0001 <1 
II 15 14, 17  8 7, 9  <0.0001 7 
III 12 11, 12  5 na  <0.0001 7 
IV 5 na  3 na  <0.0001 2 
Total 7 na  4 na  <0.0001 3 
Note: MS= median survival in months, CI = confidence interval, na= an interval 
that was too narrow to be computable. 
*The P-values are for the overall difference between the time periods for each stage. 
Discussion 
In our analysis of 288,670 lung cancer patients 
treated between 1999 and 2008, radiotherapy treat-
ment was correlated with improved OS. Notably, the 
number of NSCLC patients receiving radiation (32%) 
was nearly double that receiving surgery (16%). In an 
epidemiology study of cancer survivors between 2000 
and 2030, Bryant et al. reports a projected increase in 
radiation-treated lung cancer survivors from 16–31% 
[24]. These numbers underscore the growing 
prevalence of radiotherapy in cancer therapeutics, 
even as the incidence rate of lung cancer declines over 
recent years [3, 24, 25]. The data from the current 
study also suggest that combined radiotherapy and 
surgical treatment is correlated with enhanced 
survival outcomes comparable to that of surgery for 
stage II/III NSCLC. This trend is consistent with 
previous studies which have demonstrated the 
potential for multimodal therapy to improve 
treatment and survival outcomes for NSCLC [26, 27].  
The chronologic impact of technological 
advances in radiation was analyzed during two 
consecutive time periods: 1999–2003 and 2004–2008. 
The earlier time period (1999–2003) reflects the time 
before the full availability of advanced technologies in 
radiotherapy. The latter time period (2004–2008) 
reflects the time after the availability of advanced 
imaging and radiation-delivering technologies. In this 
study, radiotherapy treatment during 2004–2008 
showed improved survival compared to 1999–2003. 
Interestingly, stage I NSCLC showed significant 
improvement in survival with radiotherapy treatment 
but not with surgery, possibly due to the introduction 
of new technologies such as stereotactic body 
radiation therapy (SBRT). While stereotactic radiation 
was first used cranially in the 1950s, SBRT became 
FDA approved in 2001 for extracranial treatment of 
tumors and quickly showed promise in the treatment 
of various tumor sites including the lung [28, 29]. 
SBRT uses multiple radiation beams to precisely 
deliver high doses to tumor targets in extracranial 
sites. Before the advent of SBRT, surgical resection 
was the standard treatment for stage I NSCLC, 
achieving 5-year survival rates of 60–70% [28]. The 
emergence of SBRT has improved lung cancer 
survival across various countries, with survival rates 
comparable to that of surgery [30-32]. The 
Netherlands, for example, has witnessed the growth 
of SBRT utilization in the treatment of lung cancer 
over the course of 10 years [33]. In a population-based 
study of elderly Dutch patients with stage I NSCLC, 
Haasbeek et al. [34] found increases in survival for 
patients seen between 2001 and 2009, the years 
encompassing the introduction and full availability of 
SBRT treatment. 
 Journal of Cancer 2019, Vol. 10 
 
http://www.jcancer.org 
173 
 
Figure 2. In the 224,655 patients who did not undergo surgery, radiotherapy is correlated with greater OS across all stages. 
 
Table 3. Radiation improved overall survival. 
Stage Radiation   No Radiation  Radiation Difference 
N % pt MS (95% CI)  N %pt MS ( 95% CI)  *P value MS Gain (months) 
I 7473 14% 18 (18, 19)  9732 18% 12 (11, 12)  <0.0001 6 
II 1931 18% 15 (14, 15)  1484 14% 7 (7, 9)  <0.0001 8 
III 29795 40% 11 (n/a, n/a)  31935 43% 4 (n/a, n/a)  <0.0001 7 
IV 50325 43% 5 (n/a, n/a)  62865 54% 3 (n/a, n/a)  <0.0001 2 
Unknown 4109 13% 12 (n/a, n/a)  25006 78% 5 (4, 5)  <0.0001 7 
Total 93633 32% 8 (n/a, n/a)  131022 45% 4 (n/a, n/a)  <0.0001 4 
Note: MS=median survival in months, CI = confidence interval, pt = patient, na= an interval that was too narrow to be computable. 
*The P-values are for the overall difference between the time periods for each stage. 
Among NSCLC patients receiving radiotherapy without surgery, radiotherapy improved median survival across all stages. 
 
Table 4. Stage and overall survival stratified by time period. 
Stage   % of Overall Survival (95% CI) 
# Pts % pts MS ( 95% CI )  1 Yr  2 Yr   3 Yr  5 Yr 
1999-2008 Total         
I 53764 19% 49(48, 50)   78.7 (78.3, 79.0)  65.7 (65.3, 66.2)  56.9 (56.4, 57.3)  45.2 (44.7, 45.8) 
II 10937 4% 27 (26, 29)   71.0 (70.1, 71.9)  53.3 (52.3, 54.3)  42.3 (41.2, 43.3)  29.8 (28.7, 30.9) 
III 74570 26% 9 (9, 10)   41.7 (41.3, 42.1)  24.0 (23.7, 24.3)  16.6 (16.3, 16.9)  10.6 (10.4, 10.9) 
IV 117228 41% 4 (n/a, n/a)   19.7 (19.5, 20.0)  8.5 (8.3, 8.7)  4.9 (4.7, 5.0)  2.4 (2.3, 2.5) 
Unknown 32171 11% 7 (6, 7)  34. 9 (34.4, 35.5) 21.4 (20.9, 21.9) 15.2 (14.7, 15.6)  9.5 (9.1, 9.9) 
Total 288670 100% 8 (n/a, n/a)   40.0 (39.9, 40.2)  26.3 (26.2, 26.5) 20.2 (20.1, 20.4)  14.5 (14.3, 14.7) 
         
1999-2003 Total         
I 27469 20% 44 (43, 46)  76.1 (75.6, 76.6)  63.3 (62.7, 63.8) 54.4 (53.8, 55.0)  43.2(42.6, 43.8) 
II 4382 3% 28 (27, 30)  73.1 (71.7, 74.4)  54.2 (52.7, 55.6) 41.5 (40.1, 42.9)  30.0 (28.7, 31.4) 
III 40305 29% 9 (n/a, n/a)  39.3 (38.8, 39.8)  22.1 (21.7, 22.5) 15.1 (14.8, 15.5)  9.6 (9.4, 9.9) 
IV 53293 39% 4 (n/a, n/a)  17.8 (17.5, 18.1)  7.2 (6.9, 7.4) 4.1 (3.9, 4.2)  2.0 (1.9, 2.1) 
Unknown 12514 9% 7 (6, 7)  33.7 (32.9, 34.5)  18.9 (18.2, 19.6) 12.3 (11.7, 12.9)  7.3 (6.8, 7.7) 
Total 137963 100% 8 (n/a, n/a)  38.9 (38.6, 39.1)   25.3 (25.0, 25.5)  19.3 (19.1, 19.5)  13.8 (13.6, 14.0) 
         
2004-2008 Total         
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Stage   % of Overall Survival (95% CI) 
# Pts % pts MS ( 95% CI )  1 Yr  2 Yr   3 Yr  5 Yr 
I 26295 17% 56 (54, 58)  81.6 (81.1, 82.1)  68.6 (68.0, 69.3) 60.1 (59.4, 60.9)  NA 
II 6555 4% 27 (26, 29)  69.5 (68.3, 70.7)  52.9 (51.5, 54.2) 42.2 (40.7, 43.7)  NA 
III 34265 23% 10 (10, 11)  44.8 (44.2, 45.3)  26.7 (26.2, 27.3) 18.8 (18.2, 19.3)  NA 
IV 63935 42% 4 (n/a, n/a)  21.6 (21.2, 21.9 )  9.9 (9.6, 10.1) 5.7 (5.5, 5.9)  NA 
Unknown 19657 13% 6 (6, 7)  35.9 (35.2, 36.6)  23.5 (22.9, 24.2) 18.0 (17.3, 18.6)  NA 
Total 150707 100% 9 (8, 9)  41.2 (41.0, 41.5)   27.5 (27.3, 27.8)  21.3 (21.1, 21.6)  NA 
Note: MS= median survival in months, CI = confidence interval, na= an interval that was too narrow to be computable. 
 
 
 
Figure 3. Survival between the time period of 1999–2003 and 2004–2008. A-D: Among all primary NSCLC patients (n=288,670), overall survival improved 
significantly for patients with stage I, stage, III, and stage IV NSCLC between the time periods 1999–2003 and 2004–2008 (P<0.0001). E-H: Among the 93,633 patients 
receiving radiotherapy, treatment given during the recent time period (2004–2008) is correlated with enhanced OS compared to the earlier time period (1999–2003). 
 Journal of Cancer 2019, Vol. 10 
 
http://www.jcancer.org 
175 
 
Figure 4. In the 10,838 patients receiving surgery, survival improved in the recent years (2004–2008) compared to the earlier years (1999–2003) only in stage III and 
stage IV NSCLC. Overall survival did not increase significantly for stage I and stage II NSCLC. 
 
 
Figure 5. Among the 131,022 patients who did not receive surgery or radiotherapy, survival improved between the time periods 1999–2003 and 2004–2008 across 
every stage. 
 
 In the United States, the first phase I clinical trial 
of SBRT was conducted in 2003; Timmerman et al. [35] 
found that medically inoperable patients with 
early-stage NSCLC experienced significantly 
improved treatment outcomes with SBRT. In light of 
this encouraging data and in anticipation of 
widespread use of this innovative technology. 
RTOG236 the only SBRT multicenter trial was 
approved in the year of 2002, kicked off in 2003, and 
became widely adopted around 2004. The American 
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Society of Therapeutic Radiology and Oncology 
(ASTRO) and the American College of Radiology 
(ACR) developed guidelines in 2004 for integrating 
SBRT into the standard treatment of lung cancer [36]. 
Since then, numerous ongoing studies have assessed 
the role of SBRT in various clinical settings and have 
found high rates of tumor control exceeding 90% [16, 
37, 38]. Indeed, our data show improved survival 
during this time period after implementation of the 
2004 ASTRO and ACR guidelines. Improved survival 
may also be impacted by novel imaging techniques 
which could contribute to stage migration, or the Will 
Rogers phenomenon. Further investigation is 
warranted to elucidate the nuanced roles of these 
novel technologies [39-42]. 
There are several limitations to our study. SEER 
data were observational and retrospective, and lack 
information on adjuvant chemotherapy and 
radiotherapy technique [43, 44]. Nonetheless, the 
standard of care for the treatment of NSCLC is 
constantly evolving [45]. It is possible that, over the 
course of this study, patients increasingly received 
bimodal or multimodal treatments which could not be 
fully assessed in this study. Importantly, recent 
advancements in targeted therapy and immuno-
therapy have ushered a new era of precision radiation 
oncology that harnesses radiobiological mechanisms 
and technology-driven improvements to improve 
therapeutic outcomes for patients with NSCLC [21, 
46-48]. Combined immunoradiotherapy has shown 
promise in improving survival outcomes by 
capitalizing on the synergistic anti-tumor responses to 
the two treatment modalities, and several trials are 
underway to explore this topic [17, 18, 46-49]. 
Understanding the features of genomic instability that 
influence anti-tumor response and identifying the 
DNA repair biomarkers will help guide the use of 
immune-directed therapies combined with 
radiotherapy [9, 50-52]. In a phase I KEYNOTE-001 
trial, radiotherapy was shown to improve 
progression-free survival and OS among NSCLC 
patients treated afterward with pembrolizumab [17]. 
These findings warrant further trials to more fully 
assess the long-term impact of radiotherapy in 
combination with immunotherapy[53].  
Conclusions 
This large population-based study of 288,670 
patients with primary NSCLC shows that radio-
therapy is correlated with improved survival 
outcomes and is increasingly utilized in the treatment 
of NSCLC. Our study represents one of the largest 
population-based studies performed to date of 
radiotherapy and survival in lung patients across all 
stages. Combined surgery and radiotherapy 
treatment correlate with improved survival, as 
compared to other treatment modalities. Our data 
also provide supporting evidence for the potential of 
recent advances in radiotherapeutic technologies to 
enhance survival outcomes in NSCLC. As treatment 
regimens evolve to utilize multimodal and targeted 
therapy alongside innovative technology, we enter a 
new era of personalized clinical oncology that 
promises to improve survival outcomes for patients 
with NSCLC through a tailored radiotherapeutic 
approach. 
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